Quick Facts
Plain-English Summary
Glutathione (GSH) is not a novel research compound — it is an endogenous tripeptide present in virtually every cell in the human body, and is the most abundant intracellular antioxidant known. It is produced continuously from three amino acids (glutamate, cysteine, and glycine) through a two-step enzymatic process, and participates in a wide range of essential biological functions: neutralising reactive oxygen species, regenerating vitamins C and E, supporting Phase II liver detoxification, and maintaining the redox balance that governs immune cell function. Its biology is well-established and not in dispute. The scientific questions concern not what glutathione does physiologically, but whether exogenous administration — via IV, IM, oral, or topical routes — meaningfully raises systemic levels and produces the claimed clinical effects.
Research interest in exogenous glutathione spans several distinct contexts that should not be conflated. Parkinson's disease research explored IV glutathione as a neuroprotective agent, based on the observation that substantia nigra GSH depletion is an early feature of the disease — but the key pilot study by Sinha et al. involved only nine patients and no control group. Liver disease applications are supported by mechanistic plausibility (GSH is central to hepatic detoxification), with some evidence from alcoholic hepatitis data, though rigorous RCT-level evidence is limited. The skin-lightening indication is the most publicly visible and commercially driven application, supported by a small number of RCTs — most notably Weschawalit et al. (JAAD, 2017) — showing modest, reversible reductions in melanin index with oral glutathione over 12 weeks.
The oral bioavailability problem has historically complicated this field. Standard oral glutathione is largely hydrolysed in the gut before reaching systemic circulation, meaning that most tablet and capsule formulations produced minimal elevation in plasma or intracellular GSH levels. Newer liposomal oral formulations have demonstrated measurably better absorption in pharmacokinetic studies, though long-term clinical outcome data for these forms remains sparse.
The skin-lightening use case carries significant regulatory complexity. The FDA has not approved any form of glutathione for skin lightening. The Philippines FDA issued warnings against IV glutathione skin-whitening formulations citing unknown long-term risks. WHO has flagged the practice as a public health concern in certain markets. Small RCT evidence exists for oral forms, but effect sizes are modest and reversibility upon discontinuation has been documented.
The overall evidence picture is mixed by indication. The antioxidant mechanism and endogenous biology are well-characterised (high confidence). Evidence for specific clinical benefits from exogenous administration is moderate at best and indication-dependent. The compound is generally well-tolerated given its endogenous nature, but IV administration for aesthetic purposes specifically carries regulatory and safety concerns that distinguish it from straightforward supplementation.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Weschawalit S et al. — Skin Lightening | 60 healthy Thai women; oral GSH 500 mg/day vs. placebo; double-blind RCT; 12 weeks | — | Small RCT |
| Sinha R et al. — Parkinson's Disease | 9 patients with early Parkinson's disease; open-label pilot; IV glutathione 1,400 mg twice daily, 4 weeks | — | Open-Label Pilot |
| Mendoza FA et al. — Systemic Sclerosis | Early-phase clinical study; IV glutathione in systemic sclerosis (scleroderma) patients with Raynaud's phenomenon | — | Early Phase |
| Alcoholic Hepatitis — IV GSH | Multiple small studies; IV glutathione in patients with alcoholic hepatitis and elevated liver enzymes | — | Mixed |
| All other indications | Anti-aging, heavy metal chelation, immune enhancement, cancer prevention | — | No Adequate Data |
Glutathione has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Standard and liposomal oral glutathione formulations are generally well tolerated in clinical studies to date. No significant organ toxicity has been documented. As an endogenous molecule, it is not expected to be inherently toxic, though high-dose supplementation over extended periods has not been studied comprehensively in humans.
Intravenous and intramuscular administration introduce risks not present with oral use: injection site reactions, venous irritation, and rare but documented cases of anaphylaxis have been reported with IV glutathione products. The risk profile is particularly relevant in the unregulated IV skin-lightening context where sterility, dosing, and formulation quality may vary significantly.
- Injection site redness, pain, bruising (IV/IM)
- Nausea and GI discomfort (oral, high dose)
- Headache — typically transient
- Skin rash or flushing reported in some IV users
- Theoretical zinc depletion with very high dose / prolonged use
- Pregnancy and breastfeeding — insufficient safety data
- Chemotherapy patients — antioxidant interference with oxidative mechanisms of some cytotoxic agents
- Individuals with sulphite sensitivity
- IV skin-whitening outside regulated clinical settings
- Unverified IV/IM products from unregulated sources
Glutathione is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Glutathione for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The fundamental problem with glutathione supplementation discourse is that people treat plasma GSH as if it's the same thing as intracellular GSH. It isn't. Cells synthesise their own GSH from precursors — primarily cysteine, which is the rate-limiting substrate. Exogenous GSH in plasma gets rapidly hydrolysed by gamma-glutamyl transferase on cell surfaces; what gets taken up intracellularly is largely the individual amino acids, not intact GSH. This is why N-acetylcysteine — a cysteine donor — often produces better-documented intracellular GSH elevation than direct GSH supplementation. The liposomal oral data is more interesting because it may partially bypass that hydrolysis, but even then, the intracellular data is thin.
Exactly right on NAC. The Richie et al. RCT on oral GSH is actually one of the better-designed studies here and did show dose-dependent increases in whole blood and erythrocyte GSH after 6 months — which is more relevant than plasma. It's not a dramatic effect but it's real. The problem is the wellness industry has inflated what that means clinically. Elevated erythrocyte GSH is not the same as preventing cancer or reversing aging.
Worth being clear about the skin lightening data: the Weschawalit RCT is a real study and the effect is real, but it needs to be understood in context. Sixty subjects over 12 weeks, modest effect size on melanin index, and the effect reversed when supplementation stopped. That's actually what you'd expect mechanistically — tyrosinase inhibition isn't permanent structural change to melanocytes. The wellness industry sells it as "permanent whitening," which is not what the data shows. And all of that is oral GSH — the IV whitening drip market that triggered the Philippines FDA warning is operating entirely without evidence and with real injection safety risks on top.
The Parkinson's story is the most mechanistically compelling and simultaneously the most frustrating from an evidence standpoint. GSH depletion in the substantia nigra is genuinely one of the earliest measurable changes in PD pathology — it precedes dopamine depletion. The biological rationale for repleting it is solid. But the Sinha pilot is 9 patients with no control group from 1996. That's not a foundation for anything clinical. There have been no adequately powered RCTs on IV GSH in Parkinson's despite 30 years of knowing this mechanism. That gap tells you something about how hard it is to get funding for a non-patentable molecule.
This is the honest summary for most of this compound's profile — compelling mechanism, endogenous relevance, no commercial incentive to run expensive trials on an off-patent molecule. The evidence gap isn't necessarily signal that it doesn't work. It's signal that the research infrastructure hasn't caught up. That's a different problem than BPC-157, where the mechanism is still hypothetical in humans.
From a clinical standpoint, the most important thing to understand is that NAC is already the established intervention for GSH depletion in acute liver injury — paracetamol overdose, alcoholic hepatitis — and it works precisely because it donates cysteine for endogenous GSH synthesis. Direct IV glutathione in liver disease has less robust data than NAC and isn't standard of care anywhere. The wellness IV glutathione drip market is largely operating in a space that clinical hepatology moved past years ago. For general antioxidant support, the most evidence-based approach is still dietary — cruciferous vegetables upregulate GSH synthesis pathways more reliably than most supplementation protocols.